IL116203A - Pharmaceutical compositions for the treatment of emesis comprising (2s, 3s) -3-(2-methoxybenzylamino)-2-phenylpiperidine and ondansetron - Google Patents

Pharmaceutical compositions for the treatment of emesis comprising (2s, 3s) -3-(2-methoxybenzylamino)-2-phenylpiperidine and ondansetron

Info

Publication number
IL116203A
IL116203A IL11620395A IL11620395A IL116203A IL 116203 A IL116203 A IL 116203A IL 11620395 A IL11620395 A IL 11620395A IL 11620395 A IL11620395 A IL 11620395A IL 116203 A IL116203 A IL 116203A
Authority
IL
Israel
Prior art keywords
methoxybenzylamino
phenylpiperidine
emesis
ondansetron
treatment
Prior art date
Application number
IL11620395A
Other languages
English (en)
Other versions
IL116203A0 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23387561&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL116203(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of IL116203A0 publication Critical patent/IL116203A0/xx
Publication of IL116203A publication Critical patent/IL116203A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL11620395A 1994-12-09 1995-11-30 Pharmaceutical compositions for the treatment of emesis comprising (2s, 3s) -3-(2-methoxybenzylamino)-2-phenylpiperidine and ondansetron IL116203A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/353,049 US5576317A (en) 1994-12-09 1994-12-09 NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis

Publications (2)

Publication Number Publication Date
IL116203A0 IL116203A0 (en) 1996-01-31
IL116203A true IL116203A (en) 2003-07-31

Family

ID=23387561

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11620395A IL116203A (en) 1994-12-09 1995-11-30 Pharmaceutical compositions for the treatment of emesis comprising (2s, 3s) -3-(2-methoxybenzylamino)-2-phenylpiperidine and ondansetron

Country Status (11)

Country Link
US (1) US5576317A (fr)
EP (1) EP0715855A3 (fr)
JP (1) JP3372156B2 (fr)
KR (1) KR100197452B1 (fr)
CN (1) CN1082371C (fr)
AU (1) AU717776B2 (fr)
CA (1) CA2164689C (fr)
IL (1) IL116203A (fr)
MY (1) MY116002A (fr)
NZ (1) NZ280626A (fr)
ZA (1) ZA9510431B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122006000066I2 (de) * 1991-05-31 2007-12-06 Pfizer Chinuclidinderivate
RU2114848C1 (ru) * 1991-06-20 1998-07-10 Пфайзер Инк. Фторалкоксибензиламинные производные азотсодержащих гетероциклов, фармацевтическая композиция, способ ингибирования действия вещества р у млекопитающих
DK0533280T4 (da) * 1991-09-20 2005-02-28 Glaxo Group Ltd Ny medicinsk anvendelse af tachykininantagonister
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
EP2301562B1 (fr) * 1994-12-12 2013-04-17 Omeros Corporation Solution d'irrigation et utilisation de celle-ci pour inhiber périopérativement la douleur, l'inflammation et/ou les spasmes
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
BR9509985A (pt) 1995-12-12 1998-11-03 Omeros Med Sys Inc Solução para irrigação e método para inibição de dor inflamação e esparmo
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
KR100529512B1 (ko) * 1997-04-18 2005-11-22 얀센 파마슈티카 엔.브이. 장 세척 촉진을 위한 5ｈｔ3 길항제의 용도
US6087348A (en) * 1997-12-01 2000-07-11 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating stress disorders
WO2000048581A2 (fr) * 1999-02-18 2000-08-24 Novartis Ag Utilisation d'antagonistes du recepteur 5-ht¿3?
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
US20040092511A1 (en) * 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
US6770262B2 (en) 2000-03-30 2004-08-03 Questcor Pharmaceuticals, Inc. Nasal administration of agents for the treatment of gastroparesis
US6610720B2 (en) * 2000-08-24 2003-08-26 Merck Frosst Canada & Co. Method for treating or preventing emesis
KR20030036834A (ko) * 2000-09-26 2003-05-09 다나베 세이야꾸 가부시키가이샤 5-페닐벤질아민 화합물, 그의 제법 및 그의 합성 중간체
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
EP1205855A3 (fr) * 2000-11-10 2006-01-25 Masae Yanagi Méthode, système et appareil de gestion de données, appareil de manipulation de données, programme informatique et support d'enregistrement
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
JP2005522436A (ja) * 2002-02-08 2005-07-28 グラクソ　グループ　リミテッド ピペリジルカルボキシアミド誘導体またはそのタキキニン介在疾患の治療における使用
US20060205724A1 (en) * 2002-05-29 2006-09-14 The Regents Of The University Of California Antagonizing nk-1 receptors inhibits consumption of substances of abuse
AU2004204827B2 (en) * 2003-01-13 2006-06-29 Dynogen Pharmaceuticals, Inc. Method of treating nausea, vomiting, retching or any combination thereof
EP1558081A4 (fr) * 2003-01-13 2006-06-14 Dynogen Pharmaceuticals Inc Methode de traitement de troubles intestinaux fonctionnels
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
US20040204455A1 (en) * 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
DE102004033902A1 (de) * 2004-07-14 2006-02-16 Zentaris Gmbh Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's)
WO2006061707A2 (fr) * 2004-12-09 2006-06-15 Element Six Technologies (Pty) Ltd Procede d'amelioration de la perfection cristalline de cristaux de diamant
US20110201597A1 (en) 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
PL2376075T3 (pl) * 2008-12-22 2015-08-31 Evoke Pharma Inc Donosowe preparaty z metoklopramidu
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
SG174389A1 (en) 2009-03-17 2011-10-28 Daiichi Sankyo Co Ltd Amide derivative
AU2010296044B2 (en) 2009-09-18 2015-05-14 Chase Pharmaceuticals Corporation Method and composition for treating Alzheimer-type dementia
US9446029B2 (en) 2010-07-27 2016-09-20 Colorado State University Research Foundation Use of NK-1 receptor antagonists in management of visceral pain
CN102755338A (zh) * 2011-04-26 2012-10-31 齐鲁制药有限公司 含有福沙吡坦和盐酸帕洛诺司琼的复方制剂及其制备方法
WO2016118540A1 (fr) * 2015-01-20 2016-07-28 Xoc Pharmaceuticals, Inc. Traitement et/ou prévention du vomissement et/ou de la nausée comprenant la nausée et/ou le vomissement aigu et/ou retardé
WO2018112061A1 (fr) 2016-12-15 2018-06-21 Evoke Pharma, Inc. Traitement d'une gastroparésie modérée et grave

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0533280T4 (da) * 1991-09-20 2005-02-28 Glaxo Group Ltd Ny medicinsk anvendelse af tachykininantagonister
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
GB9317987D0 (en) * 1993-08-26 1993-10-13 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
JPH08225464A (ja) 1996-09-03
EP0715855A2 (fr) 1996-06-12
MY116002A (en) 2003-10-31
ZA9510431B (en) 1997-06-09
AU4030695A (en) 1996-06-20
CN1132625A (zh) 1996-10-09
AU717776B2 (en) 2000-03-30
KR100197452B1 (ko) 1999-06-15
JP3372156B2 (ja) 2003-01-27
NZ280626A (en) 1997-06-24
KR960021024A (ko) 1996-07-18
US5576317A (en) 1996-11-19
EP0715855A3 (fr) 1999-01-20
CA2164689C (fr) 1999-03-16
CN1082371C (zh) 2002-04-10
IL116203A0 (en) 1996-01-31
CA2164689A1 (fr) 1996-06-10

Similar Documents

Publication Publication Date Title
IL116203A (en) Pharmaceutical compositions for the treatment of emesis comprising (2s, 3s) -3-(2-methoxybenzylamino)-2-phenylpiperidine and ondansetron
HUP9700709A3 (en) 1,2-diphenylpyrrole derivatives, use thereof and pharmaceutical compositions containing these compounds
HU0500549D0 (en) Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof
IL135366A0 (en) Substituted benzoxazoles and pharmaceutical compositions containing the same
IL125735A0 (en) Pharmaceutical compositions for the treatment of glaucoma
HUP9800792A3 (en) Benzylpiperidines and piperazines, their use and pharmaceutical compositions containing the same
IL114622A (en) 5-membered heteroaryl-oxazolidinones and pharmaceutical compositions containing them
AU2126097A (en) Dental compounds, compositions and products
EP0950665A4 (fr) Proteines modifiees physiologiquement actives et compositions medicamenteuses les contenant
NZ329176A (en) 2,5-dioxo-imidazolidine derivatives and medicaments
HUP9900881A3 (en) 4,5-diaryl oxazole derivatives and pharmaceutical compositions containing them
IL131319A0 (en) 3-Piperidyl-4- oxoquinazoline derivatives and medicinal compositions containing the same
EP0803255A4 (fr) Composition medicinale
GB9706842D0 (en) Pharmaceutical compositions for the treatment of rhinitis
HUP9903166A3 (en) Medicinal compositions for the prophylaxis or treatment of arteriosclerosis
NZ335078A (en) Composition, for the treatment of asthma, containing loratadine and a decongestant
EP0612513A3 (en) External skin treatment composition.
BG102667A (en) Diosgenine-containing composition
HUP9702480A3 (en) New polymorphous form of doxazosin-mesylate (form. i.), process for it's preparation and pharmaceutical compositions containing the same
HUP9903649A3 (en) Taxane derivatives, the preparation thereof and medical formulations containing them
HUP9701115A3 (en) N-acetonylbenzamide derivatives, process for the preparation thereof, fungicide compositions containing these compounds and use thereof
HUT77557A (hu) Fehérítő hatású szemcsés anyagok, alkalmazásuk és ezeket tartalmazó készítmények
IL109866A (en) Crystalline 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine(+)L-hydrogentartrate its preparation and pharmaceutical compositions containing it
IL115982A0 (en) Cyclolignan derivatives and pharmaceutical compositions containing the same
ZA972708B (en) Pharmaceutical compositions and methods for the manufacture thereof.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees